Are SMS Pharmaceuticals Ltd latest results good or bad?

SMS Pharmaceuticals Ltd reported its financial results for Q4 FY26, showcasing a mixed performance. The company achieved net sales of ₹237.95 crores, reflecting a sequential growth of 13.07% from ₹210.45 crores in the previous quarter, although this represents a decline of 4.13% compared to ₹248.20 crores in Q4 FY25. The consolidated net profit for the quarter surged to ₹32.71 crores, indicating a significant quarter-on-quarter increase of 39.37% from ₹23.47 crores, and a year-on-year growth of 60.97%. However, the operating margin experienced a contraction, falling to 16.77% from 20.74% in the previous quarter, marking the weakest performance in three quarters. This decline in margins is attributed to a notable 40% increase in employee costs, which rose to ₹29.47 crores from ₹21.05 crores in Q3 FY26. The profit after tax margin also compressed to 8.81% from 11.02% in the previous quarter. For the full fiscal year FY25, SMS Pharmaceuticals reported total sales of ₹782.00 crores, representing a 10.30% increase over the previous fiscal year. The company’s return on equity stands at 11.57%, which, while positive, is below the industry average for high-quality pharmaceutical companies. The financial results have led to an adjustment in the company's evaluation, reflecting the market's sensitivity to the margin dynamics and operational efficiency. The company has demonstrated strong long-term returns, with a significant increase in share value over the past three years, but recent volatility has raised concerns among investors regarding the sustainability of profit growth amidst margin pressures. Overall, while SMS Pharmaceuticals has shown resilience in revenue recovery and profit growth, the challenges related to margin compression and rising operational costs warrant careful monitoring moving forward.